APVO - Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday? | Benzinga
Thursday, Alligator Bioscience AB and Aptevo Therapeutics Inc (NASDAQ:APVO) released interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for solid tumors likely to express the tumor antigen 5T4.
The multi-center, dose-escalation trial is now more than 50% enrolled, and preliminary results include:
- Treatment was overall well-tolerated, and a maximum tolerated dose has not yet been determined.
- Dose escalation in higher-dose cohorts is ongoing.
- ALG.APV-527 could be measured ...